Marshall Fordyce, M.D., currently serves as the President and Chief Executive Officer at VERA THERAPEUTICS INC CLASS A, a role he has held with distinction. Dr. Fordyce's professional journey in the biopharmaceutical industry is marked by his extensive experience and leadership in drug development and commercialization. He earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania. His career trajectory includes significant positions at major companies such as Genentech and Gilead Sciences, where he honed his skills in clinical development and strategic leadership. At Genentech, Dr. Fordyce played a pivotal role in the development and launch of several blockbuster drugs, contributing to the company's robust portfolio and market success. His tenure at Gilead Sciences saw him spearheading the clinical development of therapies for infectious diseases, further solidifying his reputation as a visionary in the field. As the President and CEO of VERA THERAPEUTICS, Dr. Fordyce has been instrumental in steering the company towards its mission of developing transformative treatments for serious immunological diseases. Under his leadership, VERA THERAPEUTICS has made significant strides in advancing its clinical pipeline and fostering a culture of innovation and excellence. Dr. Fordyce's achievements extend beyond his corporate roles; he is also recognized for his contributions to medical literature and his mentorship of emerging professionals in the biopharmaceutical sector. His strategic vision and dedication to patient care continue to drive VERA THERAPEUTICS forward, positioning the company as a leader in the development of novel therapies for immunological disorders.